Шановні коритсувачі репозитарію! В період з 31.12.2025 по 12.01.2026 на сервері репозитарію будуть виконуватися технічні роботи. Не намагайтеся в цей період розміщувати або редагувати свої роботи. Дякуємо за розуміння. Dear repository users! From 12/31/2025 to 01/12/2026, technical work will be performed on the repository server. Please do not attempt to post or edit your work during this period. Thank you for your understanding.
 

Pro- and anti-inflammatory biomarkers in non-alcoholic fatty liver disease and hypertension patients

dc.contributor.authorRozhdestvenska, Anastasiia
dc.contributor.authorZhelezniakova, Natalia
dc.date.accessioned2023-05-20T15:50:26Z
dc.date.available2023-05-20T15:50:26Z
dc.date.issued2023
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) affects up to 50% of patients with hypertension (HT). The objective of our study was to assess the changes in anti-inflammatory systems (kallistatin, IL-10) and pro-inflammatory activity (IL-1β and high-sensitivity CRP (hsCRP)) in patients with NAFLD under the influence of concomitant HT.en_US
dc.identifier.citationRozhdestvenska A. Pro- and anti-inflammatory biomarkers in non-alcoholic fatty liver disease and hypertension patients/ A. Rozhdestvenska, N. Zhelezniakova // 1st International Conference For Young Scientists – Biomarkers Of Civilization Diseases, April 21, 2023, Poland, Bialystok : Book of Abstracts. – Bialystok, 2023. – P. 94.en_US
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/32078
dc.language.isoenen_US
dc.subjectbiomarkersen_US
dc.subjectNAFLDen_US
dc.subjecthypertensionen_US
dc.titlePro- and anti-inflammatory biomarkers in non-alcoholic fatty liver disease and hypertension patientsen_US
dc.typeThesisen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ICYS-2023-Rozhdestvenska_Zhelezniakova.pdf
Size:
793.16 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
11.22 KB
Format:
Item-specific license agreed upon to submission
Description: